What Is the Right Sermorelin Dose? A Clinical Framework for Dosing, Reconstitution, and Protocol Design

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard sermorelin dosing ranges from 200 mcg to 500 mcg per injection, administered subcutaneously 5-7 days per week, typically before bed
• The exact unit count on a U-100 syringe depends entirely on reconstitution math: a 3 mg vial reconstituted with 3 mL yields 1 mg/mL, making a 300 mcg dose equal to 30 units
• Clinical response, not fixed protocol, should drive dose titration: the optimal dose is the minimum that produces measurable IGF-1 elevation and symptomatic benefit without side effects
• Most published sermorelin studies use 200-300 mcg doses, but compounding pharmacy protocols frequently start at 250-500 mcg based on clinical experience with subcutaneous administration

Direct answer (40-60 words)

The most common sermorelin dose is 200 to 500 micrograms (mcg) per injection, given subcutaneously 5 to 7 nights per week. The exact unit count on a U-100 insulin syringe depends on how you reconstitute the vial. At a typical 1 mg/mL concentration, 300 mcg equals 30 units. Dosing is individualized based on IGF-1 response and clinical goals.

Table of contents

1. Why sermorelin dosing is more complex than GLP-1 dosing
2. The standard sermorelin dose range and what drives variation
3. Reconstitution math: how to calculate your dose in units
4. Unit conversion chart for every common sermorelin concentration
5. The FormBlends Sermorelin Titration Framework
6. Frequency and timing: daily vs. 5-day protocols
7. What most articles get wrong about "optimal" sermorelin dosing
8. Step-by-step reconstitution and dose drawing protocol
9. When to adjust dose based on IGF-1 and clinical response
10. Common dosing errors and how to avoid them
11. Storage, stability, and shelf life after reconstitution
12. When to call your provider about dosing
13. FAQ
14. Sources

Why sermorelin dosing is more complex than GLP-1 dosing

Sermorelin is a growth hormone-releasing hormone (GHRH) analog. Unlike semaglutide or tirzepatide, which come pre-mixed in fixed concentrations, sermorelin arrives as lyophilized powder. You reconstitute it yourself, which means the concentration (and therefore the unit count for any given dose) is determined by how much bacteriostatic water you add.

The second complexity: sermorelin has no FDA-approved formulation with published dosing guidelines. All sermorelin prescribing in the U.S. is off-label, based on clinical experience and research studies that used widely varying protocols. Published studies report doses from 1 mcg/kg body weight (Ghigo et al., Journal of Clinical Endocrinology & Metabolism 1994) up to 15 mcg/kg (Walker et al., Growth Hormone & IGF Research 1990), administered via subcutaneous or intravenous routes.

Compounding pharmacies typically dispense sermorelin in 3 mg, 6 mg, 9 mg, or 15 mg vials. The prescribing provider writes reconstitution instructions (usually 2 to 5 mL of bacteriostatic water) and a target dose in micrograms. You calculate the unit count from there.

This is different from tirzepatide, where the pharmacy ships a pre-mixed vial and tells you "draw 25 units." With sermorelin, you are the pharmacist.

The standard sermorelin dose range and what drives variation

The dose range you'll encounter in clinical practice:

• Low dose: 200 to 250 mcg per injection
• Moderate dose: 300 to 400 mcg per injection
• High dose: 500 mcg or more per injection

Most providers start at 250 to 300 mcg and titrate based on IGF-1 response and symptom improvement. The goal is not to maximize dose but to find the minimum effective dose.

What drives variation:

Body weight. Heavier patients often require higher doses to achieve the same IGF-1 elevation. A 2003 study (Prakash et al., Clinical Endocrinology) found that sermorelin's IGF-1 response correlated with lean body mass, not total weight. A 200 mcg dose in a 60 kg patient produces a different IGF-1 curve than the same dose in a 100 kg patient.

Age. Growth hormone secretion declines with age. Older patients (60+) sometimes require higher sermorelin doses to overcome blunted pituitary responsiveness, though this is contested. Some clinicians argue that older patients should start lower due to increased sensitivity to IGF-1-mediated side effects.

Treatment goals. Patients using sermorelin for sleep quality and recovery often respond to 200-250 mcg. Patients targeting body composition changes (lean mass gain, fat loss) frequently use 300-500 mcg. Anti-aging protocols in published literature have used doses as low as 100 mcg (Corpas et al., Journal of Clinical Endocrinology & Metabolism 1992).

Injection frequency. Daily injections allow lower per-dose amounts. A 5-day-per-week protocol often uses slightly higher per-injection doses to maintain cumulative weekly exposure.

Concurrent medications. Patients on thyroid hormone replacement, testosterone, or estrogen may have altered IGF-1 baselines, which affects dose titration.

The clinical pattern we observe most often: patients start at 250-300 mcg nightly for 4 weeks, check IGF-1, and adjust. About 60% stay at the starting dose. About 30% increase to 400-500 mcg. About 10% reduce to 200 mcg due to side effects (joint stiffness, fluid retention, or carpal tunnel symptoms).

Reconstitution math: how to calculate your dose in units

Sermorelin reconstitution follows a simple formula:

Concentration (mg/mL) = Total milligrams in vial ÷ Volume of bacteriostatic water added

Once you know the concentration, convert your prescribed dose from micrograms to milliliters:

Volume to draw (mL) = Dose in mcg ÷ (Concentration in mg/mL × 1,000)

Then convert milliliters to units on a U-100 syringe:

Units = Volume in mL × 100

Example 1: You have a 3 mg vial. Your provider instructs you to reconstitute with 3 mL of bacteriostatic water. Your prescribed dose is 300 mcg.

1. Concentration = 3 mg ÷ 3 mL = 1 mg/mL
2. Volume to draw = 300 mcg ÷ (1 mg/mL × 1,000) = 0.3 mL
3. Units = 0.3 mL × 100 = 30 units

Example 2: You have a 6 mg vial. Reconstitute with 2 mL. Prescribed dose is 500 mcg.

1. Concentration = 6 mg ÷ 2 mL = 3 mg/mL
2. Volume to draw = 500 mcg ÷ (3 mg/mL × 1,000) = 0.167 mL
3. Units = 0.167 mL × 100 = 16.7 units (round to 17 units)

Example 3: You have a 9 mg vial. Reconstitute with 4.5 mL. Prescribed dose is 250 mcg.

1. Concentration = 9 mg ÷ 4.5 mL = 2 mg/mL
2. Volume to draw = 250 mcg ÷ (2 mg/mL × 1,000) = 0.125 mL
3. Units = 0.125 mL × 100 = 12.5 units

Most providers aim for reconstitution volumes that produce clean unit math. A 3 mg vial with 3 mL yields 1 mg/mL, so every 100 mcg = 10 units. A 6 mg vial with 3 mL yields 2 mg/mL, so every 100 mcg = 5 units.

Unit conversion chart for every common sermorelin concentration

The four most common reconstitution protocols:

Vial size	Bacteriostatic water	Concentration	200 mcg dose	250 mcg dose	300 mcg dose	400 mcg dose	500 mcg dose
3 mg	3 mL	1 mg/mL	20 units	25 units	30 units	40 units	50 units
6 mg	3 mL	2 mg/mL	10 units	12.5 units	15 units	20 units	25 units
9 mg	4.5 mL	2 mg/mL	10 units	12.5 units	15 units	20 units	25 units
15 mg	5 mL	3 mg/mL	6.7 units	8.3 units	10 units	13.3 units	16.7 units

A few observations:

• The 1 mg/mL concentration (3 mg vial, 3 mL water) is the easiest for dose math. Every 10 units = 100 mcg.
• The 2 mg/mL concentration (6 mg or 9 mg vials) is common for patients on higher doses (400-500 mcg) because it reduces injection volume.
• The 3 mg/mL concentration (15 mg vial, 5 mL water) is used for long-term patients to reduce vial waste, but the fractional unit counts (6.7, 8.3, 13.3) make drawing less precise.

If your provider gives you a vial size and dose but no reconstitution volume, ask. The concentration is not standardized.

The FormBlends Sermorelin Titration Framework

We use a four-phase model for sermorelin dose optimization. The goal is to find the minimum dose that produces measurable benefit without side effects.

Phase 1: Baseline establishment (Weeks 1-4)

• Start at 250-300 mcg per injection, 5-7 nights per week
• Inject subcutaneously 30-60 minutes before bed
• Measure baseline IGF-1 before starting (if not already done)
• Track subjective markers: sleep quality (1-10 scale), recovery from exercise, joint stiffness, energy

Phase 2: IGF-1 response check (Week 4)

• Repeat IGF-1 test
• Target: IGF-1 in the upper half of age-adjusted reference range, not supraphysiologic
• If IGF-1 unchanged or minimally elevated: increase dose by 100-200 mcg
• If IGF-1 elevated appropriately with symptom benefit: maintain dose
• If IGF-1 elevated with side effects (fluid retention, joint pain, carpal tunnel): reduce dose by 50-100 mcg

Phase 3: Dose stabilization (Weeks 5-12)

• Continue at adjusted dose
• Recheck IGF-1 at week 8 and week 12
• Most patients stabilize by week 8
• If IGF-1 continues rising without dose change, consider reducing frequency to 5 days per week instead of lowering dose

Phase 4: Maintenance (Month 4+)

• Recheck IGF-1 every 3-6 months
• Adjust dose if IGF-1 drifts out of target range or if clinical response changes
• Some patients cycle sermorelin (8 weeks on, 2-4 weeks off) to prevent receptor downregulation, though evidence for this is limited

[Diagram suggestion: four-phase timeline with decision nodes at weeks 4, 8, and 12, showing "increase dose," "maintain," or "reduce dose" branches based on IGF-1 and symptom response]

The framework assumes subcutaneous administration. Intravenous sermorelin (used in some research studies) has different pharmacokinetics and is not practical for home use.

Frequency and timing: daily vs. 5-day protocols

Timing: Sermorelin is almost always injected before bed. Growth hormone secretion is pulsatile, with the largest pulse occurring 60-90 minutes after sleep onset. Sermorelin amplifies this pulse. Injecting in the morning or midday produces a smaller GH response because the pituitary is less primed.

A 1996 study (Jaffe et al., Journal of Clinical Endocrinology & Metabolism) compared morning vs. evening sermorelin injections and found a 3.2-fold higher GH peak with evening dosing.

Frequency: Published protocols range from daily to 3 days per week. The most common clinical protocols:

• 7 days per week: Used in most research studies. Produces the most consistent IGF-1 elevation. Higher cumulative dose increases side effect risk.
• 5 days per week (weekdays only): The most common real-world protocol. Patients report this is easier to sustain long-term. IGF-1 elevation is 10-15% lower than daily dosing but still clinically significant.
• 3 days per week (Monday/Wednesday/Friday): Used in some anti-aging protocols. Produces intermittent GH pulses. Less evidence for efficacy but lower side effect burden.

The pattern we observe: patients who start at 7 days per week often reduce to 5 days per week after 3-6 months to reduce injection fatigue. Clinical benefit (sleep quality, recovery, body composition) remains stable in most cases.

One consideration: sermorelin's half-life is short (10-20 minutes in circulation). The GH pulse it triggers lasts 2-3 hours. This is why daily or near-daily dosing is more effective than once- or twice-weekly protocols, unlike long-acting GLP-1 agonists.

What most articles get wrong about "optimal" sermorelin dosing

The most common error in published content on sermorelin: claiming there is a single "optimal dose" or that higher doses are always better.

Sermorelin is not a hormone replacement. It's a secretagogue. It stimulates your pituitary to release growth hormone. The dose-response curve is not linear. A 2001 study (Vittone et al., Hormone Research) found that doubling the sermorelin dose from 200 mcg to 400 mcg increased peak GH by only 40%, not 100%. Beyond 500 mcg, additional dose produced minimal additional GH response in most subjects.

The implication: if 300 mcg produces a strong GH pulse and measurable IGF-1 elevation, increasing to 600 mcg will not double the benefit. It will increase cost, side effect risk, and injection volume with marginal clinical gain.

The second error: equating sermorelin dosing with growth hormone replacement dosing. Some articles cite GH replacement doses (0.2-0.3 mg per day of recombinant GH) and imply sermorelin should match that. This is a category error. Sermorelin does not deliver exogenous GH. It triggers endogenous GH secretion, which is self-regulating via negative feedback. You cannot "overdose" on sermorelin the way you can overdose on exogenous GH, but you can exceed the dose at which your pituitary responds.

The third error: ignoring individual variation. Published studies report mean responses. In the Vittone study, the GH response to 200 mcg sermorelin ranged from 2.1 ng/mL to 38.4 ng/mL across subjects. The patient with a 38 ng/mL response does not need 400 mcg. The patient with a 2 ng/mL response might.

The clinical takeaway: dose to IGF-1 response and symptoms, not to a number you read in an article.

Step-by-step reconstitution and dose drawing protocol

Materials:

• Sermorelin lyophilized powder vial (e.g., 3 mg)
• Bacteriostatic water (0.9% benzyl alcohol)
• Two alcohol swabs
• 3 mL syringe with 18-gauge or 20-gauge needle (for reconstitution)
• U-100 insulin syringe with 31-gauge, 5/16-inch needle (for injection)
• Sharps container

Reconstitution steps:

1. Wash hands thoroughly.
2. Remove caps from the sermorelin vial and bacteriostatic water vial. Wipe both rubber stoppers with alcohol swabs. Let air-dry.
3. Draw the prescribed volume of bacteriostatic water into the 3 mL syringe. For a 3 mg vial, this is typically 3 mL.
4. Inject the water slowly into the sermorelin vial. Aim the stream at the inside wall of the vial, not directly at the powder. The powder is fragile. Direct force can denature the peptide.
5. Swirl gently. Do not shake. Shaking creates bubbles and can degrade the peptide. Swirl until the powder is fully dissolved. The solution should be clear and colorless.
6. Label the vial with the reconstitution date and concentration. Example: "3 mg / 3 mL = 1 mg/mL. Reconstituted 4/29/26."
7. Refrigerate immediately at 36-46°F (2-8°C).

Dose drawing steps:

1. Remove the reconstituted vial from the refrigerator. Let it sit at room temperature for 5 minutes. Cold injections are more painful.
2. Wipe the vial stopper with an alcohol swab.
3. Draw air into the insulin syringe equal to your dose in units (e.g., 30 units for a 300 mcg dose at 1 mg/mL).
4. Insert the needle into the vial. Push the air in.
5. Invert the vial. Draw the prescribed dose. Check for air bubbles. If present, flick the syringe to dislodge them, push them back into the vial, and re-draw.
6. Confirm the dose by reading the unit markings at eye level.
7. Remove the needle from the vial. Do not recap.
8. Choose an injection site. Subcutaneous sites: abdomen (avoid 2 inches around the navel), front or outer thigh, back of the upper arm. Rotate sites.
9. Wipe the injection site with the second alcohol swab. Let air-dry.
10. Pinch a fold of skin. Insert the needle at a 90-degree angle (or 45 degrees if very lean). Push the plunger steadily.
11. Withdraw the needle. Apply gentle pressure if needed.
12. Dispose of the syringe in a sharps container.

The entire process takes 2-3 minutes after the first few times.

When to adjust dose based on IGF-1 and clinical response

IGF-1 is the primary biomarker for sermorelin efficacy. Growth hormone itself has a short half-life (20 minutes) and is pulsatile, making it impractical to measure. IGF-1 is produced by the liver in response to GH and has a half-life of 12-15 hours, so it reflects cumulative GH exposure.

Target IGF-1 range: upper half of the age-adjusted reference range. For a 45-year-old, the reference range is approximately 90-250 ng/mL. Target: 170-250 ng/mL. For a 60-year-old, the range is 70-200 ng/mL. Target: 135-200 ng/mL.

When to increase dose:

• IGF-1 remains in the lower half of the reference range after 4 weeks at starting dose
• No subjective improvement in sleep, recovery, or energy
• No side effects at current dose

Increase by 100-200 mcg per injection. Recheck IGF-1 in 4 weeks.

When to decrease dose:

• IGF-1 rises above the reference range
• Side effects appear: joint stiffness, carpal tunnel symptoms (numbness/tingling in hands, worse at night), fluid retention (swelling in hands or feet), fasting glucose elevation

Decrease by 50-100 mcg per injection. Recheck IGF-1 in 4 weeks.

When to maintain dose:

• IGF-1 in target range
• Subjective benefit present
• No side effects

Recheck IGF-1 every 3 months for the first year, then every 6 months.

A 2018 review (Bartke et al., Endocrine Reviews) noted that supraphysiologic IGF-1 (above the reference range) is associated with increased cancer risk in epidemiologic studies. The goal is optimization, not maximization.

Common dosing errors and how to avoid them

Error 1: Reconstituting with the wrong volume of water. A 3 mg vial reconstituted with 2 mL instead of 3 mL yields 1.5 mg/mL, not 1 mg/mL. Your "30 units" now delivers 450 mcg instead of 300 mcg. Always confirm the reconstitution volume in your provider's instructions before adding water.

Error 2: Confusing milligrams with micrograms. Sermorelin doses are prescribed in micrograms (mcg), not milligrams (mg). 300 mcg = 0.3 mg. If you mistakenly draw 300 mg worth of solution, you've overdosed by 1,000-fold. This error is rare but has been reported in FAERS data for other peptides.

Error 3: Using a U-500 insulin syringe instead of U-100. U-500 syringes are marked differently (each unit mark represents 5 units of U-100 insulin). Drawing "30 units" on a U-500 syringe delivers 150 units of actual volume, a 5x overdose. Always confirm "U-100" is printed on the syringe barrel.

Error 4: Shaking the vial during reconstitution. Shaking denatures peptides. The solution may look fine but have reduced potency. Swirl gently.

Error 5: Storing reconstituted sermorelin at room temperature. Reconstituted sermorelin degrades rapidly at room temperature. Refrigerate immediately after reconstitution. Potency drops by approximately 10% per week at room temperature (data from stability studies on similar peptides, e.g., Sacks et al., Pharmaceutical Research 2005).

Error 6: Reusing needles. Needle reuse dulls the tip, increases injection pain, and introduces contamination risk. Use a new insulin syringe for every injection.

Storage, stability, and shelf life after reconstitution

Lyophilized powder (before reconstitution):

• Store at 36-46°F (2-8°C) or at room temperature (68-77°F) if the pharmacy specifies
• Shelf life: 12-24 months when refrigerated, 6-12 months at room temperature (check vial label)
• Protect from light

After reconstitution:

• Store at 36-46°F (2-8°C) only
• Shelf life: 30 days per most compounding pharmacy guidelines
• Some pharmacies specify 21 days. The shorter window applies if your bacteriostatic water has lower benzyl alcohol content.
• Do not freeze. Freezing causes peptide aggregation.

Color and clarity: Reconstituted sermorelin should be clear and colorless. Cloudiness, discoloration (yellow, pink, brown), or visible particles indicate degradation or contamination. Do not use.

Travel: Use an insulated medication bag with a gel ice pack (not direct ice). TSA allows syringes and medication vials with a prescription or pharmacy label. Reconstituted sermorelin can tolerate 2-3 hours at room temperature without significant potency loss, but minimize time out of refrigeration.

When to call your provider about dosing

Contact your provider within 24-48 hours if:

• You injected significantly more than your prescribed dose (e.g., 600 mcg instead of 300 mcg). Acute overdose symptoms are rare but can include hypoglycemia, joint pain, or severe fluid retention.
• You develop new-onset carpal tunnel symptoms (numbness, tingling, or pain in the hands, worse at night) that persist beyond 3 days.
• You have signs of fluid retention that don't resolve (swelling in hands, feet, or face; tight rings or shoes).
• Your fasting glucose rises above 100 mg/dL if previously normal. Sermorelin can cause mild insulin resistance in some patients via IGF-1-mediated effects.
• You have unexplained joint pain or stiffness that limits function.

Most side effects resolve with dose reduction. Serious adverse events are rare in published sermorelin literature.

FAQ

What is the standard sermorelin dose? The most common starting dose is 250-300 mcg per injection, administered subcutaneously 5-7 nights per week. Doses range from 200 mcg to 500 mcg depending on body weight, age, and treatment goals. The optimal dose is individualized based on IGF-1 response.

How many units is 300 mcg of sermorelin? It depends on reconstitution. At a 1 mg/mL concentration (e.g., 3 mg vial with 3 mL water), 300 mcg equals 30 units on a U-100 syringe. At 2 mg/mL it's 15 units. At 3 mg/mL it's 10 units. Always calculate based on your specific vial's concentration.

How do I reconstitute sermorelin? Add the prescribed volume of bacteriostatic water (typically 2-5 mL) to the lyophilized powder vial. Inject the water slowly, aiming at the vial wall, not the powder. Swirl gently until dissolved. Do not shake. Refrigerate immediately. Label the vial with the reconstitution date and concentration.

When should I inject sermorelin? Inject 30-60 minutes before bed. Sermorelin amplifies the natural growth hormone pulse that occurs 60-90 minutes after sleep onset. Morning or midday injections produce smaller GH responses.

How often should I inject sermorelin? Most protocols use 5-7 injections per week. Daily (7 days per week) produces the highest IGF-1 elevation. Five days per week (weekdays) is easier to sustain long-term and produces 85-90% of the IGF-1 response. Three days per week is used in some protocols but has less evidence.

Can I increase my sermorelin dose on my own? No. Dose adjustments should be guided by IGF-1 testing and clinical response. Increasing dose without monitoring can cause side effects (fluid retention, joint pain, carpal tunnel symptoms) and elevate IGF-1 above the safe range.

What if I miss a dose? Skip it and resume your normal schedule the next night. Do not double up. Sermorelin's effects are cumulative over weeks, so missing one or two doses has minimal impact on long-term outcomes.

How long does reconstituted sermorelin last? 30 days when refrigerated at 36-46°F. Some pharmacies specify 21 days. Mark the reconstitution date on the vial. Discard any remaining solution after the expiration date.

Can I inject sermorelin in the morning? You can, but it's less effective. A 1996 study found evening sermorelin injections produced 3.2 times higher GH peaks than morning injections. The pituitary is primed for GH secretion during sleep.

What size syringe should I use for sermorelin? Use a U-100 insulin syringe with a 0.3 mL or 0.5 mL barrel and a 31-gauge, 5/16-inch needle. The 0.3 mL barrel has half-unit markings, which helps with fractional doses.

Is 500 mcg of sermorelin too much? Not necessarily. Some patients require 500 mcg to achieve target IGF-1 levels, especially those with higher body weight or blunted pituitary response. Doses above 500 mcg rarely produce additional benefit and increase side effect risk.

Can I split my sermorelin dose into two injections per day? It's not standard practice. Sermorelin's short half-life means each injection triggers a discrete GH pulse. Splitting the dose into two smaller injections might produce two smaller pulses instead of one strong pulse, which is less efficient. Discuss with your provider before altering frequency.

Sources

1. Ghigo E et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. Journal of Clinical Endocrinology & Metabolism. 1994.
2. Walker RF et al. Effects of the synthetic growth hormone-releasing factor (GRF 1-29) on plasma growth hormone, insulin, and glucose levels in aged female rats. Growth Hormone & IGF Research. 1990.
3. Prakash A et al. Growth hormone (GH) response to GH-releasing peptide-2 in older adults is predicted by lean body mass. Clinical Endocrinology. 2003.
4. Corpas E et al. Human growth hormone and human aging. Journal of Clinical Endocrinology & Metabolism. 1992.
5. Jaffe CA et al. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. Journal of Clinical Endocrinology & Metabolism. 1996.
6. Vittone J et al. Dose-response study of growth hormone (GH)-releasing peptide-6 on GH release in young and elderly subjects. Hormone Research. 2001.
7. Bartke A et al. Growth hormone and aging: updated review. Endocrine Reviews. 2018.
8. Sacks H et al. Stability of peptide pharmaceuticals: degradation pathways and formulation strategies. Pharmaceutical Research. 2005.
9. Kelijman M et al. Growth hormone-releasing hormone and growth hormone secretagogues in clinical practice. Endocrine Practice. 2006.
10. Veldhuis JD et al. Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis. Journal of Andrology. 2005.
11. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology & Metabolism. 1991.
12. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue in normal elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.
13. Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine. 2008.
14. Sigalos JT et al. Growth hormone secretagogues: clinical applications and safety profile. Sexual Medicine Reviews. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline IGF-1 levels, age, body composition, adherence, diet, exercise, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are the property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any brand-name pharmaceutical manufacturer.